361 Capital’s Cantel Medical Corporation CMD Stock Holding History

361 Capital’s Portfolio CMD Stock Details CMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-22,528	Closed	-$2.32M	–	372
2017 Q4	$2.32M	Buy	+22,528	New	+$2.24M	0.57%	57

Other funds holding CMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Diker Management New York $112M AUM 59.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

361 Capital's CMD Position: Q1 2018 in Review

361 Capital sold out of Cantel Medical Corporation (CMD) in Q1 2018, closing a stake of 22,528 shares — an estimated $2.32M sold.

361 Capital first reported a position in CMD in Q4 2017 and held it in 1 quarter. The position peaked at $2.32M in Q4 2017. 270 funds tracked by Wall St. Rank hold CMD as of Q1 2018.

361 Capital reported no remaining Cantel Medical Corporation position as of Q1 2018 after selling out during the quarter.
361 Capital sold 22,528 Cantel Medical Corporation shares in Q1 2018, an estimated $2.32M.
361 Capital first reported a position in Cantel Medical Corporation in Q4 2017 and held it in 1 quarter.
361 Capital's Cantel Medical Corporation position peaked at $2.32M in Q4 2017.
270 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q1 2018.

Based on 361 Capital's 13F filing for Q1 2018, filed 15 May 2018.